Medical Oncologist
Genetic test results
What Does 'Variant of Uncertain — Significance' (VUS) Mean?
A VUS result sits in the middle of a five-level classification scale — it is not a harmful finding and not a reassuring one. Understanding what it means, and what it does not mean, is the first step toward knowing what to do next.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Not a diagnosis — A VUS does not mean you have a cancer-causing gene variant. It means the evidence is not yet strong enough to classify it either way.
- Not a reason to panic — Most VUS findings are reclassified as benign over time as more data accumulates in global genetic databases.
- More common in South Asian populations — Genetic reference databases have historically been built from European data, so variants seen in Indian patients are more often classified as uncertain.
- You should be told if it changes — Laboratories are expected to notify your team if a VUS is reclassified — but keeping your contact details current matters.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
A variant of uncertain significance (VUS) is a genetic change your test found where the evidence is not yet strong enough to call it harmful or harmless. It is not a cancer diagnosis and it is not a clean result. Most VUS findings are eventually reclassified as benign as genetic databases grow and more families are studied.
What is a variant of uncertain significance?
Genetic test results are classified on a five-level scale: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. A VUS sits in the middle — there is not yet enough published evidence to place it confidently on either side.
Finding a VUS is common and does not mean the laboratory made an error. It reflects the current state of science: the variant has been seen before, but not in enough families to establish what it does.
Your oncologist's advice about screening and prevention is based on your personal history, your family history, your cancer type, and any pathogenic variants found — not on the VUS alone. A VUS by itself does not change clinical management.
How long your report takes and what the testing costs depends on the genes tested and the laboratory used. Your oncology team can tell you the expected turnaround for your specific panel and what the fees include before you proceed.
What to do when you receive a VUS result
- Ask your oncologist to explain the specific variantThe gene involved, the type of change, and how it was classified all affect how relevant it is to your situation.
- Do not act on the VUS aloneClinical decisions — surgery, additional screening, preventive treatment — are not made on the basis of a VUS without other supporting evidence.
- Tell close blood relatives what was foundIf the variant is later reclassified as pathogenic, your relatives will need to know quickly. Keeping them in the loop now saves time later.
- Update your contact details with the laboratoryIf your VUS is reclassified, the laboratory needs a current address or number to reach you or your team.
- Ask about re-analysis in the futureReanalysing genetic data as databases grow is becoming more common. Ask whether your laboratory offers this and whether it carries additional cost.
- Bring detailed family history records to your next appointmentA thorough family history sometimes helps reclassify a VUS, especially if multiple relatives have had the same cancer type.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What happens if your VUS is reclassified?
If the VUS is reclassified as pathogenic or likely pathogenic, your management plan will need to be revisited. Your oncologist will discuss whether additional screening, preventive options, or family testing is now indicated.
If it is reclassified as likely benign or benign, that finding is effectively removed from consideration. It becomes a result that is no longer relevant to your care, and no action follows from it.
If it remains a VUS — which is common for years at a time — your situation does not change. You continue on the plan your oncologist set based on everything else that is known about your case.
Reclassification can happen months or years after your original test as more patients with the same variant are studied worldwide. This is why remaining reachable and keeping your healthcare team informed of address changes matters.
How does a VUS differ from a pathogenic or benign result?
| Pathogenic variant | Variant of uncertain significance (VUS) | Benign variant | |
|---|---|---|---|
| What it means | Evidence shows this change increases cancer risk | Not enough evidence yet to classify it as harmful or harmless | Evidence shows this change is not associated with increased risk |
| Does it affect clinical management? | Yes — screening, prevention or treatment decisions may change | No — management is not changed by a VUS alone | No — the finding is not clinically relevant |
| Should close relatives be tested? | Yes — first-degree relatives are usually offered testing | Not routinely recommended on the basis of a VUS alone | No — a benign result does not have implications for relatives |
| Can the classification change later? | Rarely; usually confirmed over time | Yes — most VUS are eventually reclassified, most often as benign | Rarely; usually confirmed over time |
| What happens next? | Your oncologist discusses what the finding means for your care plan | Your team monitors the literature and will contact you if it is reclassified | The result is noted and no further action is needed |
Did you know?
Patients from South Asian backgrounds receive a higher proportion of VUS results than patients from European backgrounds. The reference databases used to classify variants were built largely from studies of European populations, leaving many variants seen in Indian patients without enough evidence to classify.
As more Indian patients contribute to research and as databases expand to include more diverse populations, VUS reclassification rates in South Asian patients are expected to improve over time.
Source: American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines for the Interpretation of Sequence Variants
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does a VUS mean I am at higher risk of cancer?
Not on the basis of the VUS alone. A variant of uncertain significance means the evidence is not yet sufficient to conclude it raises risk — or that it does not. Your oncologist assesses your cancer risk using your full clinical picture: your personal cancer history, your family history, any pathogenic variants found alongside the VUS, and the cancer types your family has experienced. The VUS is set aside in that assessment until there is enough evidence to classify it.
Should my family members get tested because of my VUS?
Testing relatives is not routinely recommended for a VUS, because the variant's significance is unknown. If a relative is tested and also carries the VUS, their result is equally uncertain — and both of you are left without a clear answer. If the VUS is later reclassified as pathogenic, that changes the picture and targeted testing for your relatives would then be recommended. Your genetic counsellor can advise on what makes sense given your specific family history.
How long does it take for a VUS to be reclassified?
There is no fixed timeline. Some variants are reclassified within a year or two as new studies are published; others remain uncertain for a decade or longer. The pace depends on how many other families with the same variant are being studied globally and whether those families' cancer histories align. Variants in well-studied genes tend to be reclassified more quickly than variants in less common or less-studied genes.
Will the laboratory tell me if my VUS is reclassified?
Practices vary between laboratories. Some have active re-analysis programs and will notify your ordering clinician if a classification changes. Others reclassify only when samples are resubmitted. Ask the team who ordered your test what the laboratory's policy is, and make sure your contact details — and your oncologist's details — are current. You should not have to find out about reclassification by chance.
Can I ask for my genetic data to be reanalysed?
Yes. Some laboratories offer periodic reanalysis of stored genetic data as their databases and classification criteria are updated. Whether this is available to you depends on the laboratory that processed your test, how your data was stored, and whether you consented to future analysis at the time of testing. Ask your oncology team or genetic counsellor whether reanalysis is an option and whether additional costs apply.
Should I tell my insurer about a VUS?
This is a question for a legal or financial adviser familiar with insurance rules in India, not your oncology team. A VUS is not a confirmed pathogenic finding, but disclosure obligations vary by policy and insurer. Before volunteering the result, it is worth understanding what you are required to disclose and what the consequences of disclosure might be. Your oncology team can provide documentation of what the result means clinically if you need it for any formal process.